Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Paragraf and Archer Materials announce strategic collaboration on graphene‑based quantum devices PlanetiQ awarded $15M U.S. Air Force STRATFI contract to advance next-generation weather data from space Glydways raises oversubscribed $170M Series C as first autonomous vehicle networks enter public operation in 2026 Resolve Therapeutics and Institut Pasteur collaborate to identify Cell-Free RNA triggers in autoimmunity Novadip announces the implantation of the first two patients in its phase 3 pivotal trial of NVD003 in CPT Antevia Networks and Benetel sign strategic partnership to accelerate scalable, mission-critical outdoor private 5G
Back To News
Biovex
October 17, 2017

Biovex

Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.

Cookie Policy Website powered by 100% renewable energy Privacy Policy